Topic: Eli Lilly and Company

Lilly will not seek FDA approval for arzoxifene

AP News | 344 days ago
Eli Lilly will not ask for approval of osteoporosis drug based on study data, safety concerns

Eli Lilly & Co. said Tuesday it will not seek Food and Drug Administration approval for its developing postmenopausal osteoporosis drug because of certain study results and safety concerns. The company said the drug met its late-stage study goals of reducing the risk ...

Continue reading...  

Related Articles

The beginning of the end for corporate cloud computing?

PC Pro, UK | 8 hours ago

I really hate to say it, but it looks like I have been proven right. Readers will recall how I have been calling for transparancy in the contracts...

4-Star Stocks Eli Lilly

Motley Fool | 8 hours ago

Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugmaker...

Canadian National latest blue chip to roll past earnings expectations

Edmonton Journal, Canada | yesterday

Canadian National Railway Co., one the strongest bellwethers for the health of the Canadian economy, posted surging second-quarter profit and ...

Judge upholds patent invalidation of Lilly drug

Forbes | yesterday

Eli Lilly and Co. said Wednesday the U.S. Court of Appeals for the Federal Circuit upheld a lower court's ruling that a patent on Lilly's ...

Bonuses For GSK Pharma Sales Reps Won’t Be Tied to Sales

Wall Street Journal Health Blog | yesterday

When GlaxoSmithKline said that bonuses for its U.S. pharma sales reps will no longer be based on, you know, sales, we needed to know more!....

on Twitter
Powered by Twitter
loading
Related Videos by YouTube